TrialBritish journal of haematology2020

Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.

Ricardo García-Muñoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.